Abstract Types

Clinical Review Abstract

Late-Breaking Abstract

Trials in Progress Abstract

Abstracts selected for publication but not presentation at the Annual Meeting

Abstracts granted an exception in accordance with ASCO's Conflict of Interest Policy

Response assessment of novoTTF-100A versus best physician’s choice chemotherapy in recurrent glioblastoma.

CNS Tumors

Central Nervous System Tumors

2013 ASCO Annual Meeting

Abstract No:

J Clin Oncol 31, 2013 (suppl; abstr 2080)

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2013 Annual Meeting but not presented at the Meeting, can be found online only.

Author(s): Eric Wong, Edwin Lok, Kenneth D. Swanson, Shiva Gautam, Herbert H. Engelhard, Frank S. Lieberman, Sophie Taillibert, Zvi Ram, John L. Villano, on behalf of the EF-11 Trial Investigators; Beth Israel Deaconess Medical Center, Boston, MA; University of Illinois at Chicago, Chicago, IL; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Pitie-Salpetriere Hospital-Pierre et Marie Curie Paris VI University, Paris, France; Tel Aviv University, Tel Aviv, Israel; University of Kentucky, Lexington, KY

Abstract Disclosures


Background: The NovoTTF-100A device emits tumor treating electric fields and was tested against Best Physician’s Choice (BPC) chemotherapy in a randomized phase III trial. We analyzed post hoc the characteristics of responders and non-responders in both cohorts. Methods: Macdonald criteria were used to determine tumor response and progression. Kaplan-Meier and Chi-squared statistics were computed for time to response, response duration, progression-free survival (PFS) with and without Simon-Makuch correction, and overall survival (OS). Prognostic factors were compared using the Wilconox rank sum test. Relative hazard rates for responders and non-responders were plotted. Results: The median response duration was 7.3 versus 5.6 months for NovoTTF-100A and BPC chemotherapy respectively (p=0.0009). Five of 14 NovoTTF-100A responders but none of 7 BPC responders had prior low-grade histology. The mean cumulative dexamethasone dose was 35.9 mg for responders versus 485.6 mg for non-responders in the NovoTTF-100A cohort (p<0.0001) as compared to 525.6 mg for responders and 431.0 mg for non-responders in the BPC cohort (p=0.9520). Hazard rate analysis showed delayed tumor progression in responders compared to non-responders. The Simon-Makuch conditional plot, which adjusted for unequal progression-free states, still showed longer PFS in responders than non-responders treated with NovoTTF-100A (χ2=11.5, P=0.0007) or BPC chemotherapy (χ2=5.2, P=0.0222). The median OS was 24.8 months for responders that is longer than 6.2 months for non-responders treated with NovoTTF-100A (χ2=25.7, P<0.0001). In the BPC chemotherapy cohort, the median OS was 20.0 months for responders and 6.8 months for non-responders (χ2=5.1, P=0.0235). There was strong Pearson correlation between response and OS in NovoTTF-100A (P<0.0002) but not in BPC cohort (P=0.2952). Conclusions: Response duration, adjusted Simon-Makuch PFS and OS favor NovoTTF-100A over BPC chemotherapy. Data on prior low-grade histology and dexamethasone dose suggest potential genetic and epigenetic determinants of NovoTTF-100A response. Clinical trial information: NCT00379470.


  Other Abstracts in this Sub-Category:


1. RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).

Meeting: 2013 ASCO Annual Meeting Abstract No: 1 First Author: M. R. Gilbert
Category: Central Nervous System Tumors - CNS Tumors


2. Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-nonmethylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial.

Meeting: 2013 ASCO Annual Meeting Abstract No: LBA2000 First Author: U. Herrlinger
Category: Central Nervous System Tumors - CNS Tumors


3. A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study.

Meeting: 2013 ASCO Annual Meeting Abstract No: 2001 First Author: W. Taal
Category: Central Nervous System Tumors - CNS Tumors